Author

James Love

  • FDA

    Orphan Drugs Designations and Approvals have Something to Say about Risks

    This brief essay examines data from the U.S. Orphan Drug Act, including specifically the FDA designations of an indication for a drug to treat an orphan disease, and the likelihood that once the designation is…

    Orphan Drugs Designations and Approvals have Something to Say about Risks

  • Health Law Policy

    Perspectives on Cancer Drug Development Costs in JAMA

    By James Love Vinay Prasad and Sham Mailankody’s JAMA Internal Medicine study on the costs of research and development (R&D) when bringing a single cancer drug to market has sparked renewed discussion about how to…

    Perspectives on Cancer Drug Development Costs in JAMA